Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed467%
terminated117%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

NCT02483533
completedphase_3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

NCT02398188
completedphase_2

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

NCT03005717
completedphase_3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

NCT02397499
completedphase_2

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

NCT02568319
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02483533Phase 3

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Terminated
NCT02398188Phase 3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Completed
NCT03005717Phase 2

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Completed
NCT02397499Phase 3

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

Completed
NCT02568319Phase 2

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Completed
NCT02397525Phase 2

An Open-Label Study to Evaluate Retreatment With LIPO-202

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6